211 related articles for article (PubMed ID: 21554125)
21. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses.
Clark-Snow R; Affronti ML; Rittenberg CN
Support Care Cancer; 2018 Feb; 26(2):557-564. PubMed ID: 28871358
[TBL] [Abstract][Full Text] [Related]
23. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
[TBL] [Abstract][Full Text] [Related]
24. Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.
Navari RM; Roeland EJ
Future Oncol; 2020 Aug; 16(24):1863-1872. PubMed ID: 32543309
[TBL] [Abstract][Full Text] [Related]
25. Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update.
Patel P; Robinson PD; Phillips R; Baggott C; Devine K; Gibson P; Guilcher GMT; Holdsworth MT; Neumann E; Orsey AD; Spinelli D; Thackray J; van de Wetering M; Cabral S; Sung L; Dupuis LL
Pediatr Blood Cancer; 2023 Aug; 70(8):e30395. PubMed ID: 37178438
[TBL] [Abstract][Full Text] [Related]
26. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
27. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
28. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.
Holdsworth MT; Vo-Nguyen T
Ann Pharmacother; 2005 Nov; 39(11):1903-10. PubMed ID: 16204394
[TBL] [Abstract][Full Text] [Related]
29. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract][Full Text] [Related]
30. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
Hocking CM; Kichenadasse G
Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
32. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Navari RM; Nagy CK; Gray SE
Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
[TBL] [Abstract][Full Text] [Related]
33. Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.
Stinson J; Chan K; Lee J; Chow R; Cheon P; Giotis A; Pasetka M; Wan BA; Chow E; DeAngelis C
Ann Palliat Med; 2017 Aug; 6(Suppl 1):S13-S20. PubMed ID: 28595433
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
[TBL] [Abstract][Full Text] [Related]
35. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
38. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Rapoport B; van Eeden R; Smit T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
[TBL] [Abstract][Full Text] [Related]
39. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Cruz FM; de Iracema Gomes Cubero D; Taranto P; Lerner T; Lera AT; da Costa Miranda M; da Cunha Vieira M; de Souza Fêde AB; Schindler F; Carrasco MM; de Afonseca SO; Pinczowski H; del Giglio A
Support Care Cancer; 2012 Mar; 20(3):601-6. PubMed ID: 21465325
[TBL] [Abstract][Full Text] [Related]
40. How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.
Vanbockstael J; Coquan E; Gouerant S; Allouache D; Faveyrial A; Noal S; Delcambre C; Galais MP; Héron JF; Lefebvre AC; Sevin E; Hrab I; Polycarpe F; André M; Kaluzinski L; Gervais R; Gunzer K; Vié B; Saucier G; Lemenand N; Grellard JM; Clarisse B; Dugué AE; Joly F
Support Care Cancer; 2016 Mar; 24(3):1131-8. PubMed ID: 26268784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
